No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ZURA Zura Bio
- 3.840
- +0.270+7.56%
Close Jul 23 16:00 ET
- 3.730
- -0.110-2.86%
Post 19:32 ET
244.79MMarket Cap-2782P/E (TTM)
3.860High3.520Low410.93KVolume3.550Open3.570Pre Close1.55MTurnover2.96%Turnover RatioLossP/E (Static)63.75MShares7.63452wk High4.01P/B53.40MFloat Cap2.00052wk Low--Dividend TTM13.91MShs Float37.550Historical High--Div YieldTTM9.52%Amplitude2.000Historical Low3.770Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Zura Bio Shares Fall on Warrant Exchange Offer to Simplify Capital Structure
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
Express News | Watching Monte Rosa Therapeutics, Zura Bio; Shares See Volume Amid TipRanks Issues Report Mentioning The Two Stocks
Express News | Cantor Fitzgerald Reiterates Overweight on Zura Bio
Express News | Zura Bio Ltd: Treatment With Tibulizumab Was Generally Well Tolerated in Patients With Sjogren's Syndrome
Express News | Zura Bio Ltd: Tibulizumab (Zb-106) Was Well Tolerated and Neutralized Il-17a and Baff in a Phase 1 Study in Patients With Sjogren's Syndrome
Comments
$Zura Bio(ZURA.US$ Zura Bio Ltd: Tibulizumab (Zb-106) Was Well Tolerated and Neutralized Il-17a and Baff in a Phase 1 Study in Patients With Sjogren's Syndrome! Presents data at EULAR 2024
3
$Zura Bio(ZURA.US$
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...
1
Zura Bio Garners Enthusiastic Ratings from Analysts with a Bright Outlook.
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
1
$Zura Bio(ZURA.US$ SC 13G: Statement of acquisition of beneficial ownership by individuals-Venrock Healthcare Capital Partners III, L.P.(9.99%),VHCP Co-Investment Holdings III, LLC(9.99%), etc.
SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg